Up2Date in HER2-positive breast cancer: New therapy strategy available

January 2020

January 2020 - Up2Date in HER2-positive breast cancer: New therapy strategy available

The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer

News

17. March 2020

Corona virus and Cancer patients

We would like to share with you a comment in regard to the corona virus pandemia.

10. January 2020

Case of Excellent Response

Christmas time means family time. Often, it is the only time of the year everyone can get together.

Hallwang Clinic - Private Oncology Clinic